Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1285 • ACR Convergence 2025
Investigating the Relationship Between Brain Injury Markers and Brain Volume in Children with Systemic Lupus Erythematosus and Healthy Controls
Ganesh Ramanathan¹, Diana Valdes Cabrera², Oscar Mwizerwa³, Justine Ledochowski², Tala El Tal⁴, Sarah Mossad⁵, Ibrahim Mohamed¹, Joanna Law⁶, Lawrence Ng⁷, Paris Moaf², Asha Jeyanathan⁶, Adrienne Davis⁶, Ann Yeh⁶, Linda Hiraki², Deborah Levy², Zahi Touma⁸, Joan Wither⁹, Busisiwe Zapparoli¹⁰, Ashley Danguecan⁵ and Andrea Knight⁵, ¹The Hospital for Sick Children, Brampton, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ⁵Hospital for Sick Children, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, ⁷The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹University Health Network, Toronto, ON, Canada, ¹⁰The Hospital for Sick Children, Etobicoke, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at high risk for neuropsychiatric involvement as disease onset typically occurs during the critical period of…
Abstract Number: 1179 • ACR Convergence 2025
Efficacy and Safety of Ruxolitinib in Adult Patients With Refractory Connective Tissue Disease-Associated Macrophage Activation Syndrome
Jingjing Li¹, Ran Wang¹, Jie Chen¹, Antao xu¹, Yakai Fu¹, Yanwei Lin¹, Xiaodong Wang¹, Shuang Ye², Fang Du¹ and Qiong Fu³, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ²Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: Macrophage activation syndrome (MAS) is a rare and life-threatening complication of connective tissue diseases (CTDs), with approximately 30% of cases being refractory to standard…
Abstract Number: 1009 • ACR Convergence 2025
Pregnancy Outcomes and Comorbidities Among Individuals with Systemic Lupus Erythematosus: A Nationwide Study Using Publicly Funded Health Insurance Claims Data
Amadeia Rector¹, Sadaf Sediqi², Alyssa Howren² and Julia F Simard³, ¹Stanford University, San Francisco, CA, ²Stanford University, Palo Alto, CA, ³Stanford Medicine, Stanford, CA
Background/Purpose: Individuals with SLE are at increased risk for pregnancy complications such as preeclampsia and preterm delivery. As SLE is commonly diagnosed and active during…
Abstract Number: 0934 • ACR Convergence 2025
The Use Of Preclinical Models To Understand Drivers Of Lupus Pathogenesis
Arielle Glatman Zaretsky¹, Carley Tasker¹, Pablo Abreu¹, Ciara Torres², Li-Hong Ben¹, Scott MacDonnell¹, Andre Limnander¹ and Jamie Orengo¹, ¹Regeneron, Tarrytown, NY, ²Regeneron, Tarrytown
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease with a prevalence of 1.4-15.13/100,000 adults globally. SLE is highly heterogenous and can involve…
Abstract Number: 0663 • ACR Convergence 2025
iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Parastoo Fazeli¹, Jennifer Medlin², Andrew BitMansour³, Debra Zack⁴, Rebecca Elstrom⁵, Bertha Villa⁵, Lilly Wong⁶, John Goulding⁷, Nicholas Brookhouser⁵, Trever Greene⁵, Cara Bickers⁵, Carol Wong⁵, Beatrice Ferguson⁵, Tom Lee⁵, Jode Goodridge⁵, Marie Hu⁸, Veronika Bachanova⁸, Jeffrey Miller⁹, Bahram Valamehr⁶, Matthew Lunning¹⁰ and Vaneet Sandhu⁵, ¹UMN, ST PAUL, MN, ²University of Nebraska Medical Center, Omaha, NE, ³Fate Therapeutics, Inc., San Carlos, CA, ⁴Fate Therapeutics, Inc., Solana Beach, CA, ⁵Fate Therapeutics, Inc., San Diego, ⁶Fate Therapeutics, Inc., San Diego, CA, ⁷Fate Therapeutics, San Diego, ⁸University of Minnesota, Minneapolis, ⁹University of Minnesota, Minneaspolis, MN, ¹⁰University of Nebraska, Omaha
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy shows promise in autoimmune disease. However, autologous CAR T-cell therapy is limited by prolonged pre- and…
Abstract Number: 0639 • ACR Convergence 2025
Kidney Transplantation In Lupus Nephritis. Multicenter Study Of 103 Patients
Vanesa Calvo-Río¹, Lara Sánchez Bilbao¹, Carmen Secada-Gómez¹, Paúl Hernández Velasco², Celia González-García³, Enrique Morales⁴, María Galindo-Izquierdo⁵, Sebastián Sandoval-Moreno⁶, Josefina Cortés-Hernández⁷, César Antonio Egües Dubuc⁸, Niccolo Viveros-Pérez⁹, María Caeiro¹⁰, Adrián Mayo-Juanatey¹¹, Miriam Retuerto Guerrero¹², María Camila Osorio-Sanjuan¹³, Luis Sala¹⁴ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Nephrology, Hospital Universitario ¹² de Octubre, Madrid. Spain, Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Madrid, Spain, ⁴Nephrology, Hospital Universitario ¹² de Octubre, Madrid, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ⁶Hospital Universitario Vall D'Hebron, Barcelona, Spain, ⁷Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ⁸Donostia University Hospital, San Sebastián, Pais Vasco, Spain, ⁹Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ¹⁰Centro Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ¹¹Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ¹²Complejo Asistencial Universitario de León, Leon, Castilla y Leon, Spain, ¹³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁴Hospital Universitario de Torrejón, Madrid, Spain
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE) affecting to 40-60% of SLE. End-stage renal disease (ESRD) occurs in up…
Abstract Number: 0620 • ACR Convergence 2025
The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
Luis Daniel Fajardo Hermosillo and María Karina Lizbeth López Ramírez, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, GUADALAJARA, Jalisco, Mexico
Background/Purpose: Remission in Systemic Lupus Erythematosus (SLE) is described by the Definition of Remission in SLE (DORIS), but it is hardly achieved in clinical practice,…
Abstract Number: 0604 • ACR Convergence 2025
Assessment of the Metabolic Score for Insulin Resistance (METS-IR) and Its Associated Factors in Patients with Systemic Lupus Erythematosus
Antonio Aznar-Esquivel¹, Fuensanta Gómez-Bernal¹, María García-González², Marta Hernández Díaz¹, Juan C. Quevedo-Abeledo³, Miguel A. González-Gay⁴ and Iván Ferraz Amaro¹, ¹Servicio Canario de Salud, La Laguna, Canarias, Spain, ²Servicio Canario de Salud, La Laguna, Spain, ³Hospital Doctor Negrín, Las Palmas de Gran Canaria, Canarias, Spain, ⁴Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: The Metabolic Score for Insulin Resistance (METS-IR) is a recently developed index proposed as a predictor of cardiovascular (CV) events. In this study, we…
Abstract Number: 0838 • ACR Convergence 2025
Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States
Lisa Lindsay¹, Shu Wang², Huong Trinh¹, Yunru Huang¹, William Pendergraft¹ and Brad Rovin³, ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research LLC, Hoboken, NJ, ³The Ohio State University, Columbus, OH
Background/Purpose: Complete renal response (CRR) and flare prevention, as early markers of long-term kidney survival, are important outcomes in lupus nephritis (LN) clinical trials.Methods: This…
Abstract Number: 0381 • ACR Convergence 2025
Improving Participation in The Lupus Foundation of America’s Research Accelerated by You (RAY) Patient Registry By Understanding Patient Preference in Communication Strategies
Safoah Agyemang¹, Melicent Miller¹, Tori Justin², Lydia Oberholtzer² and Joy Buie¹, ¹Lupus Foundation of America, Washington, DC, ²Sharp Insight LLC, Montgomery County, MD
Background/Purpose: The purpose of Research Accelerated by You (RAY) is to amplify awareness about clinical research and trials and ensure lupus patient partnership in therapeutic…
Abstract Number: 0136 • ACR Convergence 2025
Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study
RITESH KUMAR MISHRA¹, SUBIN PHILIP², RIZWANA NAUSHAD², AISHWARYA GOPAL³, Chengappa Kavadichanda², CHRISTINA MARIASELVAM², RAJESH N G², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Renal involvement in primary APS is underrecognized and histologically diverse, encompassing both vascular and glomerular pathology. We aimed to describe the histopathology, outcomes of…
Abstract Number: 2649 • ACR Convergence 2025
Simultaneous Assessment of Complementary Lupus-Specific Immune Mediator-Informed Indexes Improves Their Ability to Concurrently Discern Current Disease Activity And Future Flare Risk In Systemic Lupus Erythematosus
Melissa Munroe¹, Derek Blankenship², Daniele DeFreese², Adrian Holloway², Bernard Rubin², Mohan Purushothaman², Wade DeJager³, Susan Macwana⁴, Joel Guthridge⁴, Stan Kamp⁴, Nancy Redinger⁴, Teresa Aberle⁴, Eliza Chakravarty⁴, Cristina Arriens⁴, Yangfen Li⁵, Hu Zeng⁵, Stephanie Dezzutti⁶, Peter Izmirly⁷, Uma Thanarajasingam⁵, Diane Kamen⁸, Jill Buyon⁹, Judith James⁴ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Mayo Clinic, Rochester, MN, ⁶Medical University of South Carolina, Charleston, SC, ⁷New York University Grossman School of Medicine, New York, NY, ⁸Medical University of South Carolina, Johns Island, SC, ⁹NYU Grossman School of Medicine, New York, NY
Background/Purpose: Immune dysregulation propels systemic lupus erythematosus (SLE) pathogenesis. Capturing it as lab-based screening tests could help prioritize SLE patients for early intervention and proactive…
Abstract Number: 2572 • ACR Convergence 2025
Multi-Modal Machine Learning Prediction and Phenotyping of Systemic Lupus Erythematosus Using Longitudinal EHR and Genomic Data from the All of Us Program
Hunter Sporn¹, Roshni Parulekar-Martins¹, Haopeng Wang¹, Xinran Yu¹, Jeong Yee², Youngmin Kim³, Jing Cui⁴ and Karen H. Costenbader⁵, ¹Massachusetts Institute of Technology, Boston, ²Sungkyunkwan University, Suwon, MA, South Korea, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁵Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Timely diagnosis and clinically meaningful stratification of systemic lupus erythematosus (SLE) remain major unmet needs. Existing risk models rely on limited genetic or lifestyle…
Abstract Number: 2459 • ACR Convergence 2025
Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up
Milena Delai¹, Rachel Simon¹, Eduardo Mantovani Cardoso² and Vasileios Kyttaris³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, ³Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) plays an important role in the immunomodulation of Systemic Lupus Erythematosus (SLE), reducing the risk of flares and overall mortality. However, long-term…
Abstract Number: 2442 • ACR Convergence 2025
Reduction in Extrafollicular B Cell Responses in SLE Patients after CAR T Cell Therapy
Danae-Mona Nöthling¹, Kirill Anoshkin¹, Panagiotis Garantziotis¹, Laura Bucci¹, Tobias Rothe², Jule Taubmann³, Futoshi Iwata¹, Melanie Hagen¹, Andreas Wirsching¹, Simon Völkl⁴, Fabian Müller⁵, Aline Bozec¹, Andreas Mackensen⁶, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵University Hospital of Erlangen, Erlangen, Germany, ⁶Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by aberrant B cell activation and autoantibody production. CD19-targeted chimeric antigen receptor (CAR) T-cell therapy induces a short,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].